STELARA 45 mg SOLUTION FOR INJECTION IN PRE-FILLED PEN

2. What you need to know before you use Stelara

Do not use Stelara

• If you are allergic to ustekinumabor any of the other ingredients of this medicine (listed in section 6).
• If you have an active infectionthat your doctor thinks is important.

If you are not sure if anyof the above applies to you, talk to your doctor or pharmacist before using Stelara.

Warnings and precautions

Talk to your doctor or pharmacist before you start using Stelara. Your doctor will check how you are before each treatment. Make sure you tell your doctor about any illness you have before each treatment. Your doctor will also ask if you have recently been near someone who might have tuberculosis. Your doctor will examine you and do a test to check for tuberculosis before you use Stelara. If your doctor thinks you are at risk of tuberculosis, they may give you medicines to treat it.

Watch for serious side effects

Stelara may cause serious side effects, including allergic reactions and infections. You should be aware of certain signs of illness while you are using Stelara. See the complete list of these side effects in “Serious side effects” in section 4.

Tell your doctor before using Stelara:

• If you have ever had an allergic reaction to Stelara.Check with your doctor if you are not sure.
• If you have ever had any type of cancer– this is because immunosuppressants like Stelara weaken part of the immune system. This may increase the risk of having cancer.
• If you have received treatment for psoriasis with other biologics (a medicine made from a biological source and usually given by injection)– the risk of having cancer may be higher.
• If you have had a recent infection.
• If you have any new or changing lesionswithin the area of psoriasis or on intact skin.
• If you have ever had an allergic reaction to latex or to the injection of Stelara– the packaging of this medicine contains latex, which may cause serious allergic reactions in people who are sensitive to latex. See “Watch for serious side effects” in section 4 for signs of an allergic reaction.
• If you are taking any other treatment for psoriasis and/or psoriatic arthritis– such as any other immunosuppressant or phototherapy (when your body is treated with a type of ultraviolet light (UV)). These treatments may also weaken part of the immune system. It has not been studied whether these treatments can be used together with Stelara. However, it may increase the likelihood of you getting illnesses related to a weaker immune system.
• If you have received injections to treat allergies– it is not known if Stelara can affect these treatments.
• If you are 65 years or older– you are more likely to get infections.

If you are not sure if you have any of these conditions, talk to your doctor or pharmacist before using Stelara.

Some patients have experienced lupus-like reactions during treatment with ustekinumab, including cutaneous lupus or lupus-like syndrome. Talk to your doctor immediately if you experience a red, raised, and scaly skin rash, sometimes with a darker border, in areas of the skin exposed to the sun or if they are accompanied by joint pain.

Heart attacks and strokes

In a study in patients with psoriasis treated with Stelara, heart attacks and strokes have been observed. Your doctor will regularly check your risk factors for heart disease and stroke to ensure they are being treated properly. Seek medical attention immediately if you experience chest pain, weakness, or an unusual feeling on one side of your body, facial paralysis, or abnormalities in speech or vision.

Children and adolescents

Stelara pre-filled pen is not recommended for use in children and adolescents below 18 years of age with psoriasis, as it has not been studied in this age group. For children from 6 years onwards and adolescents with psoriasis, the pre-filled syringe or vial should be used instead.

Stelara is not recommended for use in children and adolescents below 18 years of age with psoriatic arthritis, Crohn's disease, or ulcerative colitis, as it has not been studied in this age group.

Using Stelara with other medicines, vaccines

Tell your doctor or pharmacist:

• If you are using, have recently used, or might use other medicines.
• If you have been vaccinated recently or are going to have a vaccination.Certain types of vaccines (live vaccines) should not be given while you are using Stelara.
• If you received Stelara during pregnancy, inform your baby's doctor about your treatment with Stelara before your baby receives any vaccination, including live vaccines such as the BCG vaccine (used to prevent tuberculosis).Live vaccines are not recommended for your baby in the first six months after birth if you received Stelara during pregnancy, unless your baby's doctor recommends otherwise.

Pregnancy and breastfeeding

• It is recommended to avoid using Stelara during pregnancy.The effects of Stelara in pregnant women are not known. If you are a woman of childbearing age, you are advised to avoid becoming pregnant and to use adequate contraceptive measures while you are using Stelara and for at least 15 weeks after the last treatment with Stelara.
• Tell your doctor if you are pregnant, think you may be pregnant, or are planning to become pregnant.
• Stelara may pass into the placenta to the fetus.If you received Stelara during pregnancy, your baby may have a higher risk of getting an infection.
• It is important that you inform your baby's doctors and other healthcare professionals if you received Stelara during your pregnancy before your baby receives any vaccination.Live vaccines, such as the BCG vaccine (used to prevent tuberculosis), are not recommended for your baby in the first six months after birth if you received Stelara during pregnancy, unless your baby's doctor recommends otherwise.
• Ustekinumab may be excreted in breast milk in very small amounts.Tell your doctor if you are breastfeeding or plan to breastfeed. You and your doctor will decide whether you should breastfeed or use Stelara. Do not do both.

Driving and using machines

Stelara has no or negligible influence on the ability to drive and use machines.

3. How to use Stelara

Stelara should be used under the guidance and supervision of a doctor with experience in the treatment of the conditions for which Stelara is indicated.

Always follow exactly the instructions of your doctor for the administration of this medicine. If you are not sure, ask your doctor. Ask your doctor when you should have the injections and about follow-up appointments.

How much Stelara to use

Your doctor will decide how much Stelara you need to use and the duration of treatment.

Adults from 18 years of age

Psoriasis or psoriatic arthritis

• The recommended starting dose is 45 mg of Stelara.Patients weighing more than 100 kilograms (kg) may start with a dose of 90 mg instead of 45 mg.
• After the initial dose, the next dose will be given 4 weeks later and then every 12 weeks.The following doses are usually the same as the starting dose.

Crohn's disease or ulcerative colitis

• During treatment, your doctor will give you the first dose of approximately 6 mg/kg of Stelara through a drip in a vein in your arm (intravenous infusion).After the initial dose, you will receive the next dose of 90 mg of Stelara 8 weeks later and then every 12 weeks, through an injection under the skin (“subcutaneously”).
• In some patients, after the first injection under the skin, 90 mg of Stelara will be given every 8 weeks.Your doctor will decide when you should receive the next dose.

How Stelara is given

• Stelara is given by injection under the skin (“subcutaneously”).At the start of your treatment, medical or nursing staff may inject Stelara for you.
• However, you and your doctor may decide that you should inject Stelara yourself.In that case, you will be trained on how to inject Stelara yourself.
• For instructions on how to inject Stelara, see “Administration instructions” at the end of this leaflet.

Talk to your doctor if you have any questions about how to inject yourself.

If you use more Stelara than you should

If you have used or been given too much Stelara, talk to your doctor or pharmacist immediately. Always carry the medicine box with you, even if it is empty.

If you forget to use Stelara

If you miss a dose, talk to your doctor or pharmacist. Do not take a double dose to make up for forgotten doses.

If you stop using Stelara

Stopping Stelara is not dangerous. However, if you stop using it, your symptoms may come back.

If you have any other questions about using this medicine, ask your doctor or pharmacist.

4. Possible Adverse Effects

Like all medicines, this medicine may cause adverse effects, although not all people suffer from them.

Severe Adverse Effects

Some patients may have severe adverse effects that may require urgent treatment.

Allergic Reactions – these may require urgent treatment. Contact your doctor or get emergency medical help immediately if you notice any of the following signs.

• Severe allergic reactions ("anaphylaxis") are rare in the population using Stelara (may affect up to 1 in 1,000 people). The signs include:

• difficulty breathing and swallowing
• low blood pressure, which can cause dizziness or mild headaches
• swelling of the face, lips, mouth, or throat.

• Common signs of an allergic reaction include skin rash and hives (these may affect up to 1 in 100 people).

In rare cases, allergic reactions at the lung level and lung inflammation have been reported in patients treated with ustekinumab. Inform your doctor immediately if you have symptoms such as cough, difficulty breathing, and fever.

If you have a severe allergic reaction, your doctor may decide that you should not use Stelara again.

Infections – these may require urgent treatment. Contact your doctor immediately if you notice any of these signs.

• Nose or throat infections and the common cold are frequent (may affect up to 1 in 10 people).
• Chest infections are uncommon (may affect up to 1 in 100 people).
• Inflammation of the tissues under the skin ("cellulitis") is uncommon (may affect up to 1 in 100 people).
• Herpes (a type of painful rash with blisters) is uncommon (may affect up to 1 in 100 people).

Stelara may affect your ability to fight infections. Some of them could become serious and be caused by viruses, fungi, bacteria (including tuberculosis), or parasites, and include infections that occur mainly in people with a weakened immune system (opportunistic infections). Opportunistic infections of the brain (encephalitis, meningitis), lungs, and eyes have been reported in patients receiving treatment with ustekinumab.

You should watch for signs of infection while using Stelara. These include:

• fever, flu-like symptoms, night sweats, weight loss
• feeling tired or having difficulty breathing; cough that does not go away
• having hot, red, and painful skin or having a painful skin rash with blisters
• burning when urinating
• diarrhea
• visual impairment or loss of vision
• headache, neck stiffness, photosensitivity, nausea, or confusion.

Communicate with your doctor immediately if you notice any of these signs of infection, as they may be signs of infections such as chest infections, skin infections, herpes, or opportunistic infections that could have serious complications. You should also inform your doctor if you have any type of infection that does not go away or comes back. Your doctor may decide that you should not use Stelara until the infection goes away. Also, contact your doctor if you have any open cuts or ulcers that could become infected.

Skin Shedding – increased redness and skin shedding over a large area of the body may be symptoms of erythrodermic psoriasis or exfoliative dermatitis, which are serious skin disorders. If you notice any of these symptoms, you should inform your doctor immediately.

Other Adverse Effects

Frequent Adverse Effects(may affect up to 1 in 10 people):

• Diarrhea
• Nausea
• Vomiting
• Feeling tired
• Feeling dizzy
• Headache
• Itching ("pruritus")
• Back, muscle, or joint pain
• Sore throat
• Redness and pain at the injection site
• Sinusitis

Uncommon Adverse Effects(may affect up to 1 in 100 people):

• Dental infections
• Vaginal yeast infections
• Depression
• Nasal congestion or blockage
• Bleeding, bruising, hardening, swelling, and itching at the injection site
• Feeling weak
• Drooping eyelid and sinking of the muscles on one side of the face ("facial paralysis" or "Bell's palsy"), which is usually temporary
• A change in psoriasis with redness and new small, yellow, or white skin blisters, sometimes accompanied by fever (pustular psoriasis)
• Skin peeling (skin exfoliation)
• Acne

Rare Adverse Effects(may affect up to 1 in 1,000 people):

• Redness and skin shedding over a large area of the body, which may cause itching or pain (exfoliative dermatitis). Similar symptoms may develop as a natural change in psoriasis symptoms (erythrodermic psoriasis)
• Inflammation of small blood vessels, which may cause a skin rash with small red or purple bumps, fever, or joint pain (vasculitis)

Very Rare Adverse Effects(may affect up to 1 in 10,000 people)

• Blisters on the skin, which may be red and cause itching and pain (bullous pemphigoid).
• Cutaneous lupus or lupus-like syndrome (red, raised, and scaly skin rash in sun-exposed areas, possibly accompanied by joint pain).

Reporting Adverse Effects

If you experience any type of adverse effect, consult your doctor or pharmacist, even if it is a possible adverse effect that is not listed in this prospectus. You can also report them directly through the national reporting system included in Appendix V. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.

5. Storage of Stelara

• Keep this medicine out of the sight and reach of children.
• Store in the refrigerator (2°C and 8°C). Do not freeze.
• Keep the pre-loaded pen in the outer packaging to protect it from light.
• If necessary, individual pre-loaded Stelara pens can also be stored at room temperature up to 30°C for a maximum single period of up to 30 days, keeping them in their original box to protect them from light. Write the date when the pre-loaded pen is first removed from the refrigerator and the date when it should be discarded in the space provided on the outer packaging. The discard date should not exceed the original expiration date printed on the box. Once a syringe or pre-loaded pen has been stored at room temperature (up to a maximum of 30°C), it should not be stored in the refrigerator again. Discard the syringe or pre-loaded pen if it has not been used within 30 days of storage at room temperature, or if it has expired according to the original expiration date, whichever occurs first.
• Do not shake Stelara pre-loaded pens. Prolonged vigorous shaking may damage the product.

Do not use this medicine:

• After the expiration date stated on the label and packaging after "EXP". The expiration date is the last day of the month indicated.
• If the liquid changes color, is cloudy, or has foreign particles floating in it (see section 6 "Appearance of Stelara and package contents").
• If you know or believe that it has been exposed to extreme temperatures (such as accidental heating or freezing).
• If the product has been shaken vigorously.

Stelara is for single use. You should discard any unused product remaining in the syringe or pre-loaded pen. Medicines should not be disposed of through wastewater or household waste. Ask your pharmacist how to dispose of packaging and medicines that are no longer needed. This will help protect the environment.

6. Container Contents and Additional Information

Stelara Composition

• The active ingredient is ustekinumab. Each pre-filled syringe contains 45 mg of ustekinumab in 0.5 ml.
• The other components are L-histidine, L-histidine monohydrate monohydrochloride, polysorbate 80, sucrose, and water for injectable preparations.

Appearance of Stelara and Container Contents

Stelara is a slightly opalescent (with a pearlescent sheen), colorless to light yellow, transparent injectable solution. The solution may contain a few translucent or white protein particles. It is presented in a container that contains 1 pre-filled syringe of 1 ml of glass. Each pre-filled syringe contains 45 mg of ustekinumab in 0.5 ml of injectable solution.

Marketing Authorization Holder

Janssen-Cilag International NV

Turnhoutseweg 30

B-2340 Beerse

Belgium

Manufacturer

Janssen Biologics B.V.

Einsteinweg 101

2333 CB Leiden

Netherlands

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Date of Last Revision of this Leaflet

Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu/.

Instructions for Use

Stelara

(ustekinumab)

injection, for subcutaneous use

Pre-filled Syringe

These instructions for use contain information on how to inject Stelara.

Important

Stelara is presented in a single-dose pre-filled syringe that contains a dose of 45 mg or a dose of 90 mg.

If your doctor considers that you or your caregiver are able to administer your Stelara injections at home, you will receive training to prepare and inject Stelara correctly using the pre-filled syringe. Do not attempt to administer the injections alone without having received training from your doctor.

Each pre-filled syringe can only be used once. Dispose of the syringe (see step 3) after use, even if there is still medication left in it.

Do not reuse the pre-filled syringe.

Read these instructions for use before using the Stelara pre-filled syringe and each time you use a new pre-filled syringe.There may be new information. This leaflet does not replace the conversation with your doctor about your health or treatment.

If you cannot administer the injection yourself:

• ask your doctor or nurse for help, or
• ask someone who has been trained by a doctor or nurse to administer the injections.

To reduce the risk of accidental needlesticks, each pre-filled syringe has a needle shield that automatically covers the needle and locks after administering the injection and lifting the syringe. Do not lift the syringe until you have completed the injection.

The needle cap located inside the lower cap of the pre-filled syringe contains latex. Do not handle the needle cap if you are allergic to latex.

Also, read the leaflet carefully before starting to administer the injection and discuss any questions you have with your doctor or nurse.

Storage Information

Store in a refrigerator between 2 °C and 8 °C. If necessary, store at room temperature up to 30 °C for a maximum of 30 days in the original carton. Do not put it back in the refrigeratoronce stored at room temperature.

Do not freezethe pre-filled syringe.

Keep the pre-filled syringe and all medications out of the reach of children.

Do not shakethe pre-filled syringe. Shaking can damage the Stelara medication. If the pre-filled syringe has been shaken, do not use it. Use a new pre-filled syringe.

Store the pre-filled syringe in the original carton to protect it from light and physical damage.

Do you need help?

Consult your doctor with any questions you may have. For additional help or to share your experience, see the contact information of your local representative in the leaflet.

1. Preparation for Stelara injection

Take the carton(s)

If it is refrigerated, remove the carton(s) of the pre-filled syringe from the refrigerator and place it on a flat surface.

Let it stand at room temperature for at least 30 minutesbefore using.

Do notheat it in any other way.

Check the expiration date ("EXPIRY DATE") and the carton seals

Do notuse the pre-filled syringe if the carton seals are broken or if it has passed the expiration date.

Do notuse the pre-filled syringe if it has been stored at room temperature for more than 30 days or if it has been stored above 30 °C. Consult your doctor or pharmacist to obtain a new pre-filled syringe.

Choose the injection site

Choose from the following areas to administer the injection:

• Front of the thighs
• Lower abdomen (below the navel), avoiding the area 5 centimeters around the navel

If someone else is administering the injection, you can also use:

• The back of the arms

Do notinject into sensitive, bruised, red, or hardened skin.

Wash your hands

Wash your hands well with warm water and soap.

Clean the injection site

Clean the chosen injection site with an alcohol wipe and let it dry.

Do nottouch, fan, or blow on the injection site after cleaning.

Inspect the liquid in the viewer

Choose a well-lit, clean, and flat work surface.

Remove the pre-filled syringe from the carton and check for damage.

Check the liquid in the viewer. It should be clear or slightly opalescentand colorless to light yellowand may contain small white or transparent particlesand one or more air bubbles.This is normal.

Do notinject if the liquid is frozen or cloudy, has an abnormal color, or contains large particles. Consult your doctor or pharmacist to obtain a new pre-filled syringe.

1. Stelara injection

Remove the lower cap

Keep your hands away from the needle shieldafter removing the cap. It is normal to see a few drops of liquid.

Inject Stelara within 5 minutes of removing the cap.

Do notreplace the cap. This could damage the needle.

Do notuse a pre-filled syringe that has been dropped after removing the cap. Consult your doctor or pharmacist to obtain a new pre-filled syringe.

Apply directly to the skin. Press the plunger all the way down until the purple body is no longer visible.

You may hear a click when the injection starts. Continue pressing.

If you feel resistance, continue pressing. This is normal.

The medication is injected as you press. Do it at a pace that feels comfortable for you.

Confirm that your injection is complete

Your injection is complete when:

• The purple body is no longer visible.
• You cannot press the plunger any further.
• You may hear a click.

Lift the syringe straight up

The yellow line indicates that the needle shield has locked.

1. After the injection

Dispose of the pre-filled syringe

Place the used pre-filled syringe in a sharps container after use.

Do notthrow away (dispose of) the pre-filled syringes in household trash.

Do notrecycle the used sharps container.

Inspect the injection site

There may be a small amount of blood or liquid at the injection site. This is normal.

Press the injection site with a cotton ball or gauze until it stops bleeding.

Do notrub the injection site.

If necessary, cover the injection site with a band-aid.